PD-1

[Brazilian Journal of Medical and Biological Research] Lower Foxp3 and higher Bcl-6, ICOS, and PD-1 mRNA expression levels were found in patients with dilated cardiomyopathy (DCM). Plasma interleukin (IL)-6, tumor necrosis factor (TNF)-α, and IL-21 levels were significantly increased in DCM cases.

[Nature Communications] Hypothesizing that EGFR mutations alter tumor-immune interactions, scientists compared tumor-infiltrating lymphocytes between EGFR mutant and wild type tumors through single-cell transcriptomic analysis.

[Merck (BusinessWire, Inc.)] Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted positive opinions recommending approval of the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for two different indications.

[Immune-Onc Therapeutics, Inc.] Immune-Onc Therapeutics, Inc. announced that the first patient has been dosed in the company’s first-in-human clinical trial of IO-108, a novel antagonist antibody targeting the myeloid checkpoint Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) for the treatment of solid tumors.

[Modern Pathology] The proportion of T cells and their subpopulations were associated with clinicopathological features and relapse-free survival outcomes. CD3+ CD4+ infiltrates were more abundant in the patients with higher grade or non-endometrioid histology.

[Science Advances] Researchers showed that abnormal IL-36 production activated by NF-κB was an essential feature of mouse and human leukemic progenitor cells.